
## Luciano Cascione

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4600633/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer Cell, 2014, 25, 469-483.	16.8	267
2	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical Cancer Research, 2015, 21, 1628-1638.	7.0	237
3	Protective role of miR-155 in breast cancer through <i>RAD51</i> targeting impairs homologous recombination after irradiation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4536-4541.	7.1	181
4	Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer. PLoS ONE, 2013, 8, e55910.	2.5	158
5	MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non–small-cell lung cancer through BIM down-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16570-16575.	7.1	150
6	A MALT lymphoma prognostic index. Blood, 2017, 130, 1409-1417.	1.4	149
7	The genetics of nodal marginal zone lymphoma. Blood, 2016, 128, 1362-1373.	1.4	147
8	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nature Medicine, 2017, 23, 1046-1054.	30.7	145
9	microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget, 2014, 5, 1174-1184.	1.8	136
10	Regulation of acute graft-versus-host disease by microRNA-155. Blood, 2012, 119, 4786-4797.	1.4	128
11	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
12	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	8.5	121
13	miR-15b/16-2 deletion promotes B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11636-11641.	7.1	98
14	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	1.3	94
15	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	7.0	92
16	A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget, 2015, 6, 20829-20839.	1.8	89
17	Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options. PLoS ONE, 2014, 9, e88525.	2.5	79
18	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 2017, 66, 1268-1277.	12.1	75

#	Article	IF	CITATIONS
19	microRNA classifiers are powerful diagnostic/prognostic tools in <i>ALK-</i> , <i>EGFR-</i> , and <i>KRAS</i> -driven lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14924-14929.	7.1	74
20	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood, 2018, 132, 179-186.	1.4	63
21	Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget, 2015, 6, 3394-3408.	1.8	56
22	TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Research, 2015, 75, 1908-1921.	0.9	56
23	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia, 2014, 28, 1922-1926.	7.2	55
24	Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Scientific Reports, 2017, 7, 3140.	3.3	55
25	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica, 2019, 104, e558-e561.	3.5	55
26	Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARÎ <sup>2</sup> and tumor regression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9812-9817.	7.1	53
27	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	1.4	53
28	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	1.4	49
29	Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 2017, 86, 158-165.	2.8	47
30	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Advances, 2020, 4, 1082-1092.	5.2	47
31	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clinical Cancer Research, 2019, 25, 5167-5176.	7.0	43
32	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica, 2019, 104, e256-e259.	3.5	43
33	Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma. British Journal of Haematology, 2017, 178, 936-948.	2.5	42
34	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood, 2019, 133, 156-167.	1.4	40
35	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 2015, 6, 31134-31150.	1.8	38
36	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Modern Pathology, 2020, 33, 179-187.	5.5	37

#	Article	IF	CITATIONS
37	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Advances, 2020, 4, 4124-4135.	5.2	37
38	miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Research, 2014, 42, 5416-5425.	14.5	36
39	A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model. Blood, 2013, 121, 4355-4358.	1.4	31
40	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS ONE, 2019, 14, e0212813.	2.5	31
41	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	7.3	30
42	DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma. Scientific Reports, 2017, 7, 11591.	3.3	29
43	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica, 2020, 105, 2592-2597.	3.5	29
44	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of <i>CDKN1A</i> expression levels in mediating their anti-tumor response. Oncotarget, 2015, 6, 5059-5071.	1.8	29
45	miR-EdiTar: a database of predicted A-to-I edited miRNA target sites. Bioinformatics, 2012, 28, 3166-3168.	4.1	28
46	A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma. Cancer Research, 2018, 78, 5741-5753.	0.9	28
47	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica, 2019, 104, 1633-1639.	3.5	28
48	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Advances, 2020, 4, 819-829.	5.2	28
49	The genetic landscape of dural marginal zone lymphomas. Oncotarget, 2016, 7, 43052-43061.	1.8	28
50	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. British Journal of Cancer, 2016, 115, 1343-1350.	6.4	27
51	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica, 2020, 105, 2584-2591.	3.5	27
52	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of Oncology, 2016, 27, 1123-1128.	1.2	26
53	Let-7c down-regulation in <i>Helicobacter pylori</i> -related gastric carcinogenesis. Oncotarget, 2016, 7, 4915-4924.	1.8	26
54	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong <i>in vivo</i> antitumor activity in lymphoma. Oncotarget, 2016, 7, 58142-58147.	1.8	25

#	Article	IF	CITATIONS
55	Radiomics Analysis of [ <sup>18</sup> F]-Fluorodeoxyglucose-Avid Thyroid Incidentalomas Improves Risk Stratification and Selection for Clinical Assessment. Thyroid, 2021, 31, 88-95.	4.5	23
56	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open, 2018, 3, e000387.	4.5	21
57	Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia, 2013, 27, 740-743.	7.2	18
58	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. Pathology Research and Practice, 2020, 216, 152907.	2.3	17
59	MIDClass: Microarray Data Classification by Association Rules and Gene Expression Intervals. PLoS ONE, 2013, 8, e69873.	2.5	17
60	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. Oncotarget, 2014, 5, 1185-1197.	1.8	17
61	Genome-wide promoter methylation of hairy cell leukemia. Blood Advances, 2019, 3, 384-396.	5.2	16
62	Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq. PLoS ONE, 2019, 14, e0215154.	2.5	15
63	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica, 2019, 104, e307-e309.	3.5	14
64	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers, 2019, 11, 775.	3.7	14
65	Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large Bâ€cell lymphoma: postâ€hoc analysis from the SAKK38/07 clinical trial. Hematological Oncology, 2020, 38, 715-725.	1.7	14
66	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica, 2018, 103, 2049-2058.	3.5	13
67	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 2021, 28, 2970-2982.	11.2	13
68	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R HOP14: A SAKK 38/07 trial postâ€hoc analysis. Hematological Oncology, 2022, 40, 12-22.	1.7	13
69	Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACPâ€319 in preâ€clinical models of aggressive lymphomas. British Journal of Haematology, 2019, 187, 595-601.	2.5	12
70	Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization. Non-coding RNA, 2019, 5, 47.	2.6	12
71	MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. Head and Neck Pathology, 2019, 13, 344-354.	2.6	12
72	Recombinant α-interferon 2b in the treatment of HIV-related thrombocytopenia. Aids, 1993, 7, 823-828.	2.2	10

#	Article	IF	CITATIONS
73	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Advances, 2021, 5, 2467-2480.	5.2	10
74	Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Haematologica, 2022, 107, 2685-2697.	3.5	10
75	Late relapse in patients with diffuse large Bâ€cell lymphoma: impact of rituximab on their incidence and outcome. British Journal of Haematology, 2019, 187, 478-487.	2.5	9
76	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas. Frontiers in Oncology, 2020, 10, 584095.	2.8	9
77	Outcome of patients older than 80Âyears with diffuse large <scp>B</scp> â€cell lymphoma ( <scp>DLBCL</scp> ) treated with "standard―immunochemotherapy: A large retrospective study from 4 institutions. Hematological Oncology, 2018, 36, 84-92.	1.7	8
78	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. Blood, 2013, 122, 1853-1853.	1.4	8
79	KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. Oncology Reports, 2021, 47, .	2.6	8
80	RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis. BMC Bioinformatics, 2021, 22, 298.	2.6	7
81	ASB2 is a direct target of FL11 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 357.	8.6	7
82	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers, 2022, 14, 1018.	3.7	7
83	Elucidating the Role of microRNAs in Cancer Through Data Mining Techniques. Advances in Experimental Medicine and Biology, 2013, 774, 291-315.	1.6	6
84	<p>Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma</p> . Cancer Management and Research, 2019, Volume 11, 7845-7855.	1.9	6
85	Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529. Blood, 2016, 128, 4187-4187.	1.4	6
86	The novel atypical retinoid <scp>ST</scp> 5589 downâ€regulates Aurora Kinase A and has antiâ€ŧumour activity in lymphoma preâ€clinical models. British Journal of Haematology, 2015, 171, 378-386.	2.5	5
87	THE ANTIBODYâ€DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCTâ€402) TARGETING CD19 SHOWS STRONG <i>IN VITRO</i> ANTI‣YMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. Hematological Oncology, 2019, 37, 129-130.	1.7	5
88	THE ANTIâ€CD25 ANTIBODYâ€DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCTâ€301) PRESENTS A STRONO PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. Hematological Oncology, 2019, 37, 323-324.	1.7	5
89	Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. British Journal of Haematology, 2019, 184, 1022-1025.	2.5	5
90	Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. European Journal of Cancer, 2020, 138, S40.	2.8	5

#	Article	IF	CITATIONS
91	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Frontiers in Endocrinology, 2022, 13, 834075.	3.5	5
92	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the <scp>REAL</scp> 07 Phase 1–2 study. British Journal of Haematology, 2018, 182, 453-456.	2.5	4
93	cuRnet: an R package for graph traversing on GPU. BMC Bioinformatics, 2018, 19, 356.	2.6	4
94	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type. Cancers, 2020, 12, 1912.	3.7	4
95	Abstract 4275: Analysis of gene and protein expression in lymphoma cell lines using multiple platforms. , 2018, , .		4
96	Understanding the mechanism of action of pyrrolo[3,2- <i>b</i> ]quinoxaline-derivatives as kinase inhibitors. RSC Medicinal Chemistry, 2020, 11, 665-675.	3.9	4
97	EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT. Hematological Oncology, 2019, 37, 179-180.	1.7	3
98	<i>In vitro</i> demonstration of synergism with pixantrone combined with targeted agents in lymphomas. British Journal of Haematology, 2019, 186, 149-152.	2.5	3
99	Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation. Non-coding RNA, 2021, 7, 26.	2.6	3
100	Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. Haematologica, 2021, , .	3.5	3
101	Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma. , 2019, , .		3
102	Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors. Blood, 2018, 132, 4174-4174.	1.4	3
103	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. Blood, 2019, 134, 2569-2569.	1.4	3
104	Gradual Rarefaction of Hematopoietic Precursors and Atrophy in a Depleted microRNA 29a, b and c Environment. PLoS ONE, 2015, 10, e0131981.	2.5	3
105	Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures. , 2019, , .		3
106	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. Exploration of Targeted Anti-tumor Therapy, 2021, 2, 586-601.	0.8	3
107	COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B- AND T-CELL LYMPHOMAS. Hematological Oncology, 2019, 37, 318-319.	1.7	2
108	Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in		2

lymphoma models. , 2015, , .

#	Article	IF	CITATIONS
109	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. Blood, 2018, 132, 922-922.	1.4	2
110	Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103. Molecular Cancer Therapeutics, 2018, 17, B061-B061.	4.1	2
111	Abstract 2853: Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL). , 2018, , .		2
112	Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity. Blood, 2020, 136, 10-11.	1.4	2
113	Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment. Frontiers in Oncology, 0, 12, .	2.8	2
114	The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. European Journal of Cancer, 2016, 69, S38.	2.8	1
115	MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA. Hematological Oncology, 2019, 37, 319-319.	1.7	1
116	MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. Hematological Oncology, 2020, 38, 831-833.	1.7	1
117	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
118	The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma. Blood, 2014, 124, 3113-3113.	1.4	1
119	BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 4495-4495.	1.4	1
120	The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. Blood, 2015, 126, 4005-4005.	1.4	1
121	ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 1755-1755.	1.4	1
122	HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide. Blood, 2014, 124, 3377-3377.	1.4	1
123	The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2015, 126, 5119-5119.	1.4	1
124	Abstract 3829: NEO1132 and NEO2734, novel dual bromodomain inhibitors of both BET and CREBBP/EP300, compared to single BET or CREBB/EP300 inhibitors in diffuse large B cell lymphoma. , 2019, , .		1
125	Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma. Blood, 2019, 134, 2858-2858.	1.4	1
126	Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). Blood, 2019, 134, 4010-4010.	1.4	1

#	Article	IF	CITATIONS
127	Abstract PO-46: Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. , 2020, , .		1
128	P0282 : The long non coding RNA UC.158 modulates growth of Wnt/β;-catenin driven hepatocellular carcinoma (HCC). Journal of Hepatology, 2015, 62, S413-S414.	3.7	0
129	Prognostic value of the immune-related transcriptome in biliary tract cancers. Annals of Oncology, 2016, 27, vi234.	1.2	0
130	HSP-90 Inhibition is a Promising Therapeutic Strategy in Cholangiocarcinoma and MIR-21 may Serve as a Biomarker of Sensitivity. Journal of Hepatology, 2016, 64, S559.	3.7	0
131	A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study. Lecture Notes in Computer Science, 2019, , 24-32.	1.3	0
132	Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome. Annals of Oncology, 2019, 30, iv110-iv111.	1.2	0
133	Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients. Annals of Oncology, 2019, 30, v786.	1.2	0
134	THE NONCODING RNA GECPAR IS INVOLVED IN WNT SIGNALING AND HAS TUMOR-SUPPRESSOR ACTIVITY IN DIFFUSE LARGE B CELL LYMPHOMA. Hematological Oncology, 2019, 37, 77-77.	1.7	0
135	EG-011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI-TUMOR ACTIVITY AGAINST LYMPHOMA. Hematological Oncology, 2019, 37, 513-514.	1.7	0
136	Integration of Omics Data to Identify Cancer-Related MicroRNA. Methods in Molecular Biology, 2019, 1970, 85-99.	0.9	0
137	THE FIRST-IN-CLASS ETS INHIBITOR TK-216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA. Hematological Oncology, 2019, 37, 322-322.	1.7	0
138	SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematological Oncology, 2019, 37, 512-513.	1.7	0
139	THE TRANSCRIPTION FACTOR FLI1 SUSTAINS RELEVANT BIOLOGICAL PATHWAYS AND DRIVES ONCOGENES THAT PROMOTE CELL GROWTH IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematological Oncology, 2019, 37, 75-75.	1.7	0
140	Abstract 2373: Expression of exosomal let-7g in biofluids and outcome in colon cancer patient treated with anti-EGFR therapy. , 2021, , .		0
141	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients Blood, 2012, 120, 2921-2921.	1.4	0
142	Abstract 3061: Micro-RNA signature differences in lung cancer patients withALKtranslocation,EGFRmutations andKRASmutations , 2013, , .		0
143	Abstract 1951: miRNA expression profile of Blastic plasmacytoid dendritic cell neoplasm , 2013, , .		0
144	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Cell Biology, 2013, 201, i4-i4.	5.2	0

#	Article	IF	CITATIONS
145	Abstract 1122: In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation , 2013, , .		О
146	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	1.4	0
147	Abstract 2604: Characterization of the activity and the mechanism of action of the new retinoid derivative ST5589 in pre-clinical models of lymphomas: involvement of MYC and cell cycle genes. , 2014, , .		0
148	Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response. , 2014, , .		0
149	Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma. , 2014, , .		Ο
150	Abstract 3083: Global gene expression profiling of mice tumor-derived organoids identifies key microRNAs and metabolic genes involved in CRC progression. , 2015, , .		0
151	Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models. , 2015, ,		Ο
152	Abstract 1069: MiR-21 may serve as a predictive biomarker of response in the assessment of efficacy of HSP-90 inhibition in gastrointestinal (GI) cancers. , 2016, , .		0
153	Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features. , 2016, , .		Ο
154	Abstract 5179: The first in class FLI1 inhibitor TK-216 presents both in vitro and in vivo anti-tumor activity in lymphoma. , 2017, , .		0
155	Abstract B041: PQR309-containing combinations show synergistic antilymphoma activity. , 2018, , .		Ο
156	Abstract 799: The novel histone deacetylase inhibitor pracinostat is an effective anti-lymphoma agent. , 2018, , .		0
157	Abstract 796: The BTK inhibitor BGB-3111 is synergistic with other anti-lymphoma targeted agents. , 2018, , .		0
158	Abstract 906: Development of novel preclinical models of secondary resistance downstream B cell receptor in marginal zone lymphoma. , 2018, , .		0
159	Abstract 1894: Identification of novel OTX015-containing combinations for lymphoma treatment. , 2018, , .		Ο
160	New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease. Blood, 2018, 132, 4173-4173.	1.4	0
161	Early progression of disease (POD24) as survival predictor in MALT lymphoma Journal of Clinical Oncology, 2019, 37, 7548-7548.	1.6	0
162	Abstract 4796: EC-011 is a novel small molecule within vitroandin vivoanti-tumor activity against lymphoma. , 2019, , .		0

#	Article	IF	CITATIONS
163	Abstract 1805: Integrative analysis of microRNAs in blastic plasmacytoid dendritic cell neoplasm. , 2019, , .		0
164	Abstract 4206: EUD-GK-001 is a novel kinase inhibitor within vitroanti-lymphoma activity. , 2020, , .		0
165	Abstract 163: DNA methyltransferase modulation in lymphoma cells involves functional redundancy and maintains hypermethylation of selected regions. , 2020, , .		0
166	Abstract 5215: Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B cell lymphoma. , 2020, , .		0
167	Abstract 1417: Development of a miRNA-based prediction tool to discriminate cutaneous blastic plasmacytoid dendritic cell neoplasm from cutaneous myeloid sarcoma. , 2020, , .		Ο
168	Abstract PO-07: The FL11 direct target ASB2 promotes NF-KB pathway activation in diffuse large B-cell lymphoma of the germinal center B-cell type. , 2020, , .		0
169	Abstract 4735: The histone deacetylase inhibitor pracinostat modulates the transcriptome of diffuse large B-cell lymphoma cells and is active in combination with several targeted agents. , 2019, , .		0
170	Abstract 4796: EG-011 is a novel small molecule with <i>in vitro</i> and <i>in vivo</i> anti-tumor activity against lymphoma. , 2019, , .		0